AbbVie Inc. stock edges higher after lymphoma trial setback and new SkinMedica launch
Published on 09/01/2026 at 22:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie Inc. (ISIN US00287Y1091) stock is trading near recent highs, supported by a market capitalization of about USD 453.12 billion as of September 1, 2026, according to market data compiled by CompaniesMarketCap.Market capitalization data This large-cap profile gives the health care company significant weight in global equity benchmarks even as mixed clinical news emerges.
Lymphoma trial setback contrasts with robust valuation
According to a news report summarized by Ground News on September 1, 2026, AbbVie and partner Genmab disclosed a late-stage trial setback for their bispecific antibody Epkinly in diffuse large B-cell lymphoma.Clinical trial setback report Despite this negative catalyst in one oncology program, AbbVie still commands a market cap of around USD 453.12 billion at a share price near USD 256.42, illustrating that investors continue to price in the broader portfolio and cash-flow strength.Valuation snapshot
The same valuation overview indicates AbbVie’s market capitalization at USD 453.12 billion tied to a share price of USD 256.42, which is consistent with separate data points that reference a similar market cap at USD 260.24 per share.Share price comparison This alignment suggests that daily price fluctuations over late August and early September 2026 have been comparatively modest, while the absolute equity value remains high. For investors, the key comparison is between the current valuation level and AbbVie’s ability to sustain growth in oncology and immunology despite individual trial disappointments.
DACH investors track AbbVie via Tradegate listing
For investors in German-speaking markets, AbbVie stock is also accessible via the Tradegate platform, where MarketScreener shows the AbbVie share trading at around 222.50 EUR in real-time on September 1, 2026.Tradegate quotation in EUR The same overview notes a five-day performance of plus 0.82 percent and a year-to-date change of minus 2.73 percent, giving a quantified comparison: over the latest week the stock has edged up, yet it still trades below its level at the start of 2026.
A valuation page for AbbVie further underscores this picture, listing the Tradegate price at 222.30 EUR as of September 1, 2026, with a five-day gain of 0.72 percent and the same minus 2.73 percent change since January 1, 2026.Valuation metrics page This side-by-side comparison shows that the recent upward move has not yet fully offset earlier declines, which is relevant for DACH investors considering entry points or assessing performance against regional health-care peers.
AbbVie Inc. fundamentals and stock profile
Further details on AbbVie Inc., including historical earnings, dividend data and peer comparisons, are available via the dedicated ISIN page and the company’s Investor Relations site.
SkinMedica launch highlights dermatology focus
On the product side, AbbVie continues to invest in its aesthetics and dermatology franchise. A release carried by StockTitan on September 1, 2026 reports that AbbVie has added SkinMedica Barrier Calming Cream to its SkinMedica portfolio, positioning the new product as a restorative moisturizer designed to support the skin barrier.SkinMedica Barrier Calming Cream launch According to the same report, the Barrier Calming Cream is priced at USD 140, while another SkinMedica product, HA5 Hydra Collagen Facial Mist, is priced at USD 58, illustrating AbbVie’s premium positioning in professional skin-care.
This pricing comparison within the SkinMedica portfolio shows a spread of USD 82 between the Barrier Calming Cream and the HA5 Hydra Collagen Facial Mist, reflecting differentiation in formulation and use case. For AbbVie, the aesthetics and dermatology segment complements its core prescription portfolio in immunology and oncology, helping diversify revenue sources beyond traditional branded drugs. The new launch also keeps the SkinMedica brand visible in a competitive market segment where innovation and dermatologist endorsement are important.
Representative product: SkinMedica Barrier Calming Cream
SkinMedica Barrier Calming Cream is a representative example of how AbbVie uses dermatologist-focused brands to extend its reach into aesthetic medicine and advanced skin-care. The product is described as a restorative moisturizer aimed at supporting the skin’s barrier function, which can be compromised by procedures or chronic dryness, according to the launch information cited by StockTitan.Product positioning details With a price point of USD 140 as of September 1, 2026, the cream targets professional and clinic-based channels rather than mass-market retail, aligning with AbbVie’s strategy in medical aesthetics.
AbbVie Inc. stock and valuation snapshot
AbbVie Inc. stock is listed on the New York Stock Exchange under the ticker ABBV and is also traded in Europe via platforms such as Tradegate, where recent data show a price of about 222.30 EUR as of September 1, 2026.European quotation and valuation Based on a share price around USD 256 to USD 260 and a market capitalization of approximately USD 453.12 billion, AbbVie ranks among the largest global health care companies, which is relevant for both US and DACH index investors.
AbbVie Inc. stock fact box
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Trading venue: NYSE, Tradegate (secondary listing)
- Price (as of September 1, 2026): 222.30 EUR (Tradegate)
- Market capitalization: 453.12 billion USD (as of September 1, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
